Compare Albemarle Corp. (ALB) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Albemarle Corp. vs Koninklijke Philips NV — how do they compare? Albemarle Corp. trades at $127.67 (market cap $15.22B), while Koninklijke Philips NV trades at $27.55 (market cap $27.30B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays the higher dividend (3.59%). Which is the better fit depends on your goals.
| ALB | PHG | |
|---|---|---|
Market Cap | $15.22B | $27.30B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $32.91 |
52-Week Low | $67.30 | $24.03 |
Enterprise Value | $18.24B | $33.57B |
Dividend Yield | 1.26% | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) is trading at $129.02, down 4.82% over the past 24 hours amid bearish technical signals. The stock shows mixed fundamentals with a low P/E of 5.12 and negative net income margin of -4.24% for 2025, though Q1 2026 earnings beat expectations. Recent news highlights a focus on debt reduction and energy storage system demand as lithium prices rebound. Cash flow improved in 2025 with net cash flow of $425.77 million, while the balance sheet reflects a debt-to-asset ratio of 19.8%.
The outlook for ALB hinges on lithium price recovery and execution in energy storage markets. Analyst consensus is mixed with a $227.10 price target suggesting significant upside, but risks include volatile lithium markets and ongoing profitability challenges. The stock's current level near key support at $128 may attract value investors, though macroeconomic and commodity pressures remain headwinds.
PHG trades at $28.23, up 1.77% with a bullish technical outlook supported by moving averages. The company shows improved profitability with net income turning positive at $895 million in 2025 after previous losses. Recent earnings beat expectations in two of the last three quarters, while analyst sentiment leans neutral with 40.9% buy ratings. Strong cash flow generation and strategic partnerships in healthcare technology position the company for continued recovery.
The stock presents a recovery story with improving fundamentals but faces execution risks in a competitive healthcare technology market. Valuation appears reasonable with P/E of 24.73 and P/S of 1.35, though debt levels remain elevated. Near-term catalysts include Q2 2026 earnings and continued AI integration in healthcare solutions, while macroeconomic pressures and competitive threats represent ongoing challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
